Company: INVUP
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001193
Chunk: 1111

Company: Investview, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 1111
---
 meeting
    of stockholders.

Our
indemnification of our directors and officers may limit the rights of our stockholders.

While
our board of directors and officers are generally accountable to our stockholders and us, the liability of our directors and officers
to all parties is limited in certain respects under applicable state law and our articles of incorporation and bylaws, as in effect.
Further, we have agreed or may agree to indemnify our directors and officers against liabilities not attributable to certain limited
circumstances. This limitation of liability and indemnity may limit rights that our stockholders would otherwise have to seek redress
against our directors and officers.

We
may be caused to issue a substantial number of shares of our common stock to our former Chief Executive Officer if our attempts to retire
his note in cash are unsuccessful.

We
owe payment on a promissory note in the principal amount of $1,550,000 to our former Chief Executive Officer, Joseph Cammarata, (the
“Cammarata Note”). Further, the Cammarata Note is convertible into shares of our common stock at $0.008 per share. During
February 2022, we provided 30 days’ notice of our intent to retire and repay the Cammarata Note in cash. Having not timely received
a properly executed conversion notice within the proscribed period, and citing certain other damages incurred by us arising from Mr.
Cammarata’s then ongoing legal proceedings, on or about March 31, 2022, we tendered to Mr. Cammarata cash payment in full for the
Cammarata Note. As of the date of this Report, Mr. Cammarata has not accepted our tender of the cash payment, and instead during 2022
asserted his entitlement to exercise his right to convert the Cammarata Note into our common shares, although we believe his attempted
conversion was not timely, nor in compliance with the conversion features of the note. Although we believe that our cash tender was appropriate
under the terms of the Cammarata Note and otherwise at law, and Mr. Cammarata’s attempt to convert the note were ineffective, if
Mr. Cammarata elects to challenge our cash tender in a court proceeding, and if we are unable to sustain our legal position on the matter,
Mr. Cammarata could receive up to approximately 203 million shares of our common stock upon conversion of the Cammarata Note.

23

The
amount of authorized common stock may